ࡱ> 45 l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~"؈ ~~ ؈ ~~8"܈ ~~3"܈ ~~3#܈ ~~4#܈ ~~8#܈ ~~"؈ ~~9#܈ ~~83ffff̙̙3f3fff3f3f33333f33&FCALCULATION OF REGISTRATION FEE&1Neither the Securities and ExchTABLE OF CONTENTS&-.License Agreement with the Popu&7License Agreement with the (1)>DILUTIONJ UNDERWRITINGoQ Paid by UsMX PROSPECTUS l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Neither the Securities and ExchTABLE OF CONTENTS!License Agreement with the Popu!License Agreement with the (1) DILUTION UNDERWRITING Paid by Us PROSPECTUSU } 1} $ } } $ } } $ } a} $ }                      TherapeuticsMD, Inc. 424B2 08/02/2018'CALCULATION OF REGISTRATION FEE, $Title of Securities to be Registered  Amount  Proposed  Proposed   Amount of   to be  Maximum  Maximum  Registration Fee (2)   Registered (1)  Offering Price   Aggregate      per Share  Offering Price (1)1 ) Common stock, par value $0.001 per share ~ z~  ffffff@  ̰`ґA  (\/-@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hvj^C7=PF0*8X> @ l  B  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEETABLE OF CONTENTS!License Agreement with the Popu!License Agreement with the (1) DILUTION UNDERWRITING Paid by Us PROSPECTUSU } '} $                    TherapeuticsMD, Inc. 424B2 08/02/2018jbNeither the Securities and Exchange Commission nor any state securities commission has approved or    Per Share   Total  Public offering price  ffffff@  ~ I  Underwriting discounts  /$?  ~   (  Proceeds, before expenses, to us  V-@  ~ ?  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(#T?3'Mj=PF0*8X> @Z          l  7$-  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEE!Neither the Securities and Exch!License Agreement with the Popu!License Agreement with the (1) DILUTION UNDERWRITING Paid by Us PROSPECTUSU } 2} $ } } $ 7     TherapeuticsMD, Inc. 424B2 08/02/2018TABLE OF CONTENTS   Page  Prospectus Supplement      (  About this Prospectus Supplement   S-ii % Prospectus Supplement Summary   S-1  Risk Factors S-132*Cautionary Statement About Forward-Looking S-29 InformationUse of Proceeds S-31Dilution S-32 Underwriting S-33 Legal Matters S-39Experts S-39+#Where You Can Find More Information S-39,$Incorporation of Certain Information S-40 by Reference ProspectusAbout this Prospectus ii Risk Factors~ "Forward-Looking Statements~   Our Company~ *"Ratio of Earnings to Fixed Charges~ D lxl03! s'0Va !"#$%&'()*+,-./0123456 Use of Proceeds  ~  !Selling Stockholders!!~ !!"Dilution""~ """##Description of Common Stock##~ #&#&$Description of Preferred Stock$$~ $.$&%Description of Debt Securities%%~ %>%(& Description of Depositary Shares&&~ &n&'Description of Warrants''~ 'z')(!Description of Purchase Contracts((~ (()Description of Units))~ ))0*(Certain Provisions of Nevada Law and Our**~ **+Charter and Bylaws%,Legal Ownership of Securities,,~ ,,-Plan of Distribution--~ --. Legal Matters..~ ../Experts//~ //+0#Where You Can Find More Information00~ 00,1$Incorporation of Certain Information11~ 112 by Reference3$4____________________________15)Created by Morningstar Document Research.06(http://documentresearch.morningstar.com/2_af W@"u*" =PF0*8X> @"665544  l  07  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEE!Neither the Securities and ExchTABLE OF CONTENTS!License Agreement with the (1) DILUTION UNDERWRITING Paid by Us PROSPECTUSU } } $ } y } $ } m} $ }  } $ }                       TherapeuticsMD, Inc. 424B2 08/02/20185-License Agreement with the Population Council Ease of  Ease of  Ease of  Ease of  No side effects  inserting  removing   remembering   remembering   reported on (N=905)  (N=905)   CVR insertion   CVR removal   questionnaire     (N=905)  (N=905)  (N=905) 90.8%  88.2%  87.6%  85.2%  81.8%~ &~ ~ ~ ~ r$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|th\PM |T=PF0*8X> @ l  m>  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEE!Neither the Securities and ExchTABLE OF CONTENTS!License Agreement with the Popu DILUTION UNDERWRITING Paid by Us PROSPECTUSU } 0} $ } } $      TherapeuticsMD, Inc. 424B2 08/02/20185-License Agreement with the Population Council Annual Net Sales   Royalty Rate + #Less than or equal to $50.0 million  ~  %0 (Greater than $50.0 million and less than  ~ * %" or equal to $150.0 million# Greater than $150.0 million  ~ > %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hth\Pfsg?=PF0*8X> @"  l  II  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEE!Neither the Securities and ExchTABLE OF CONTENTS!License Agreement with the Popu!License Agreement with the (1) UNDERWRITING Paid by Us PROSPECTUSU } :} $                             TherapeuticsMD, Inc. 424B2 08/02/2018DILUTION' Public offering price per share      ffffff@ 8 0Net tangible book value per share as of June 30,  (\?     ~ . &Increase per share attributable to new  {Gz?       investors/'As adjusted net tangible book value perQ?4,share after this offering and the concurrentoffering3+Dilution per share to new investors in this(\@offering$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:Hu T?F}qe==PF0*8X> @B    l  P  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEE!Neither the Securities and ExchTABLE OF CONTENTS!License Agreement with the Popu!License Agreement with the (1) DILUTION Paid by Us PROSPECTUSU } U} $ } y} $      TherapeuticsMD, Inc. 424B2 08/02/2018 UNDERWRITING  Underwriters  Number of Shares  Goldman Sachs & Co. LLC  ~ N  Cantor Fitzgerald & Co.  ~ (7       Total  ~ *  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|}q5?xlD=PF0*8X> @"  l  W  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEE!Neither the Securities and ExchTABLE OF CONTENTS!License Agreement with the Popu!License Agreement with the (1) DILUTION UNDERWRITING PROSPECTUSU } } $                   TherapeuticsMD, Inc. 424B2 08/02/2018 Paid by Us    No Exercise    Full Exercise   Per Share  /$?   /$?  Total ~    ~ "   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&(@s2=PF0*8X> @J        l  %9ef  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!CALCULATION OF REGISTRATION FEE!Neither the Securities and ExchTABLE OF CONTENTS!License Agreement with the Popu!License Agreement with the (1) DILUTION UNDERWRITING Paid by UsU } 0} $ } U} $ %     TherapeuticsMD, Inc. 424B2 08/02/2018 PROSPECTUS ABOUT THIS PROSPECTUS   ii   RISK FACTORS  ~  " FORWARD-LOOKING STATEMENTS  ~     OUR COMPANY  ~  * "RATIO OF EARNINGS TO FIXED CHARGES  ~  USE OF PROCEEDS~ SELLING STOCKHOLDERS~ DILUTION~ "#DESCRIPTION OF COMMON STOCK~ &&DESCRIPTION OF PREFERRED STOCK~ .&DESCRIPTION OF DEBT SECURITIES~ >( DESCRIPTION OF DEPOSITARY SHARES~ nDESCRIPTION OF WARRANTS~ z)!DESCRIPTION OF PURCHASE CONTRACTS~ DESCRIPTION OF UNITS~ 0(CERTAIN PROVISIONS OF NEVADA LAW AND OUR~ CHARTER AND BYLAWS%LEGAL OWNERSHIP OF SECURITIES~ PLAN OF DISTRIBUTION~  LEGAL MATTERS~ EXPERTS~ +#WHERE YOU CAN FIND MORE INFORMATION~ ,$INCORPORATION OF CERTAIN INFORMATION~ D ls7BL[E?`~ !"#$  BY REFERENCE!$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/P=PF0*8X> @$$##"" Root Entry FBook  g  !"#$%&'()*+,-./0123